Commission Implementing Regulation (EU) 2016/950

of 15 June 2016

amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 2,4-DB, beta-cyfluthrin, carfentrazone ethyl, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), cyazofamid, deltamethrin, dimethenamid-P, ethofumesate, fenamidone, flufenacet, flurtamone, foramsulfuron, fosthiazate, imazamox, iodosulfuron, iprodione, isoxaflutole, linuron, maleic hydrazide, mesotrione, oxasulfuron, pendimethalin, picoxystrobin, silthiofam and trifloxystrobin

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC1, and in particular the first paragraph of Article 17 thereof,

Whereas:

(1)
Part A of the Annex to Commission Implementing Regulation (EU) No 540/20112 sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009.
(2)
The approval periods of the active substances carfentrazone ethyl, cyazofamid, ethofumesate, fenamidone, foramsulfuron, imazamox, isoxaflutole, linuron, mesotrione, oxasulfuron, pendimethalin and trifloxystrobin were derogated from by Commission Regulation (EU) No 823/20123. The approval of those substances will expire on 31 July 2016.
(3)

The approval periods of the active substances 2,4-DB, beta-cyfluthrin, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), deltamethrin, dimethenamid-P, flufenacet, flurtamone, fosthiazate, iodosulfuron, iprodione, maleic hydrazide, picoxystrobin and silthiofam were derogated from by Regulation (EU) No 823/2012. The approval of these substances will expire on 31 October 2016.

(4)
Applications for the renewal of the approval of those substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/20124.
(5)

Due to the fact that the assessment of the substances has been delayed for reasons beyond the control of the applicants, the approvals of those active substances are likely to expire before a decision has been taken on their renewal. It is therefore necessary to extend their approval periods.

(6)

In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission will adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission will set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later. As regards cases where the Commission will adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.

(7)

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

(8)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 15 June 2016.

For the Commission

The President

Jean-Claude Juncker

ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

  1. (1)

    in the sixth column, expiration of approval, of row 29, Ethofumesate, the date is replaced by ‘31 July 2017’;

  2. (2)

    in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2017’;

  3. (3)

    in the sixth column, expiration of approval, of row 41, Imazamox, the date is replaced by ‘31 July 2017’;

  4. (4)

    in the sixth column, expiration of approval, of row 42, Oxasulfuron, the date is replaced by ‘31 July 2017’;

  5. (5)

    in the sixth column, expiration of approval, of row 44, Foramsulfuron, the date is replaced by ‘31 July 2017’;

  6. (6)

    in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2017’;

  7. (7)

    in the sixth column, expiration of approval, of row 47, 2,4-DB, the date is replaced by ‘31 October 2017’;

  8. (8)

    in the sixth column, expiration of approval, of row 48, Beta-cyfluthrin, the date is replaced by ‘31 October 2017’;

  9. (9)

    in the sixth column, expiration of approval, of row 50, Iprodione, the date is replaced by ‘31 October 2017’;

  10. (10)

    in the sixth column, expiration of approval, of row 51, Linuron, the date is replaced by ‘31 July 2017’;

  11. (11)

    in the sixth column, expiration of approval, of row 52, Maleic hydrazide, the date is replaced by ‘31 October 2017’;

  12. (12)

    in the sixth column, expiration of approval, of row 53, Pendimethalin, the date is replaced by ‘31 July 2017’;

  13. (13)

    in the sixth column, expiration of approval, of row 59, Trifloxystrobin, the date is replaced by ‘31 July 2017’;

  14. (14)

    in the sixth column, expiration of approval, of row 60, Carfentrazone ethyl, the date is replaced by ‘31 July 2017’;

  15. (15)

    in the sixth column, expiration of approval, of row 61, Mesotrione, the date is replaced by ‘31 July 2017’;

  16. (16)

    in the sixth column, expiration of approval, of row 62, Fenamidone, the date is replaced by ‘31 July 2017’;

  17. (17)

    in the sixth column, expiration of approval, of row 63, Isoxaflutole, the date is replaced by ‘31 July 2017’;

  18. (18)

    in the sixth column, expiration of approval, of row 64, Flurtamone, the date is replaced by ‘31 October 2017’;

  19. (19)

    in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2017’;

  20. (20)

    in the sixth column, expiration of approval, of row 66, Iodosulfuron, the date is replaced by ‘31 October 2017’;

  21. (21)

    in the sixth column, expiration of approval, of row 67, Dimethenamid-P, the date is replaced by ‘31 October 2017’;

  22. (22)

    in the sixth column, expiration of approval, of row 68, Picoxystrobin, the date is replaced by ‘31 October 2017’;

  23. (23)

    in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2017’;

  24. (24)

    in the sixth column, expiration of approval, of row 70, Silthiofam, the date is replaced by ‘31 October 2017’;

  25. (25)

    in the sixth column, expiration of approval, of row 71, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), the date is replaced by ‘31 October 2017’.